Paris-based Sanofi-aventis April 8 announced that it has completed the acquisition of Genzyme Corp., which is now a wholly owned subsidiary of Sanofi.
In February, Sanofi and Genzyme announced that they had a definitive agreement for Sanofi to acquire Genzyme for $74 per share in chase, or about $20.1 billion (9 PLIR 212, 2/18/11).
Genzyme, which is based in Cambridge, Mass., will become an important new platform in Sanofi’s sustainable growth strategy and expand the company’s presence in biotechnology, Sanofi said.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.